Ladenburg Thalmann launched coverage of Immutep of Australia (NASDAQ:IMMP) with a “buy” rating and $8.30. The stock closed at $3.46 0n Aug. 2. Immutep is a clinical-stage immuno-oncology company focused on developing...
Maxim Group transferred primary coverage of Immutep (NASDAQ:IMMP) to analyst, Naureen Quibria, Ph.D., with a “buy” rating and $8 price target. The stock closed at $3.53 on July 15. Immutep has a pipeline of...